Comparison of Outcomes Between Radical Nephrectomy and Partial Nephrectomy in Clinical T2 Renal Cell Carcinoma: A Retrospective Korean Renal Cell Carcinoma Cohort Study

Article information

J Urol Oncol. 2024;22(2):136-143
Publication date (electronic) : 2024 July 31
doi : https://doi.org/10.22465/juo.244800360018
1Department of Urology, Seoul National University Bundang Hospital, Seongnam, Korea
2Department of Urology, Seoul National University College of Medicine, Seoul, Korea
3Department of Urology, Seoul National University Hospital, Seoul, Korea
4Department of Urology, Korea University Anam Hospital, Seoul, Korea
5Department of Urology, Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul, Korea
6Department of Urology, Chungbuk National University Hospital, Cheongju, Korea
7Department of Urology, National Cancer Center, Goyang, Korea
8Department of Urology, Chonnam National University Medical School, Gwangju, Korea
9Department of Urology, Kyungpook National University Chilgok Hospital, Daegu, Korea
10Department of Urology, Asan Medical Center, Seoul, Korea
Corresponding author: Jung Kwon Kim Department of Urology, Seoul National University Bundang Hospital, Seoul National University College of Medicine, 82 Gumi-ro 173beon-gil, Bundang-gu, Seongnam 13620, Korea Email: andss1@hanmail.net
Received 2024 April 30; Revised 2024 June 24; Accepted 2024 July 8.

Abstract

Purpose

We compared the surgical outcomes of radical nephrectomy (RN) and partial nephrectomy (PN) in adult patients with clinical T2 stage (cT2) renal cell carcinoma (RCC) by utilizing data from the Korean Renal Cell Carcinoma (KORCC) database.

Materials and Methods

We retrospectively analyzed adult patients with cT2 RCC from 8 tertiary hospitals who were registered in the KORCC between 2003 and 2023. Patients with a solitary kidney or bilateral tumors were excluded. The patient cohort was divided into RN and PN arms, and propensity score matching (PSM) was conducted with a 1:3 ratio. Perioperative and survival outcomes were compared between arms.

Results

After PSM, the PN and RN arms included 44 and 132 patients, respectively. No significant differences were observed in baseline characteristics, apart from laterality, following PSM. Regarding perioperative outcomes, complications of Clavien-Dindo classification grade III or higher (11.4%, p<0.001) and urological complications (9.1%, p=0.045) were more common in the PN arm than in the RN arm. Postoperative renal function was superior in the PN arm, whereas the incidence of de novo chronic kidney disease (CKD) at 6 months was higher among the recipients of RN (37.6%, p<0.001). Pathological examination indicated a higher pathological T stage in the RN arm. Overall, cancer-specific, and recurrence-free survival rates did not differ significantly between arms. Based on Cox regression analysis, the use of PN was not a significant predictor of recurrence-free survival (hazard ratio, 0.675; p=0.474).

Conclusions

In cT2 RCC, PN was associated with a lower incidence of de novo CKD than RN. No significant differences in survival outcomes were noted. PN may represent a viable alternative to RN for certain patients with cT2 RCC. Further research is warranted to explore the management of advanced RCC.

INTRODUCTION

Renal cell carcinoma (RCC) represents 2.2% (n=431,288) of all newly diagnosed cancers, with a mortality rate of 1.8% (n=179,368) according to 2020 GLOBOCAN data [1]. Over the past 2 decades, surgical approaches to RCC have evolved [2]. Compared to radical nephrectomy (RN), partial nephrectomy (PN) has demonstrated benefits in preserving renal function [3,4]. The principle of nephron preservation is thought to play a role in patient prognosis, prompting the increased use of PN [5-9]. Consensus indicates that PN should be the treatment of choice for T1-stage tumors when feasible [2]. However, the optimal approach for T2 tumors is still under debate. Although RN remains the gold standard for tumors of stage T2 or higher, several recent reviews have suggested that PN may represent a viable alternative for T2 tumors [3,10-12].

In South Korea, the Korean Renal Cell Carcinoma (KORCC) registry has been established as a multicenter RCC database [13]. This study aimed to leverage the KORCC database to aid in determining whether to perform PN or RN in patients with stage T2 RCC. By utilizing data from the KORCC registry for clinical T2 (cT2) RCC cases, the study retrospectively compared outcomes between PN and RN.

MATERIALS AND METHODS

The study was conducted in accordance with the STROBE (Strengthening the Reporting of Observational Studies in Epidemiology) guidelines. The research focused on adult patients with cT2 RCC, identified from 8 tertiary hospitals in the KORCC database between 2003 and 2023. Specifically, patients with a postoperative pathologic confirmation of RCC were included. The exclusion criteria encompassed patients with a solitary kidney, bilateral renal tumors, pathologic stage N1 (pN1), or pathologic stage M1 (pM1). The patient cohort was subsequently divided into PN and RN arms based on the surgical method employed.

1. Variable Outcomes

Baseline characteristics such as age, sex, body mass index (BMI), history of diabetes mellitus (DM), history of hypertension (HTN), smoking history, American Society of Anesthesiologists physical status classification, serum creatinine level, C-reactive protein (CRP) level, neutrophillymphocyte ratio (NLR), Modification of Diet in Renal Disease Study equation-estimated glomerular filtration rate (eGFR), radiologic tumor size, RENAL nephrometry score (radius, exophytic/endophytic, nearness to collecting system or sinus, anterior/posterior, and location relative to polar lines), symptoms at diagnosis, tumor laterality, and cT stage were assessed. Perioperative outcomes, including operative time, estimated blood loss (EBL), ischemic time, intraoperative complications, and postoperative complications, were evaluated. Ischemic time was assessed exclusively for the PN arm. Postoperative complications were compared in terms of both overall and—more specifically— urologic complications. Within each category, comparisons were also made for Clavien-Dindo classification grade 3 or higher complications. Kidney function was evaluated at 1, 3, and 6 months postoperatively. The presence of de novo chronic kidney disease (CKD) was assessed at 6 months. De novo CKD is defined as the new postoperative occurrence of CKD, as evidenced by eGFR declining to 60 mL/min/1.73 m2 or lower. Recurrence, all-cause mortality, and RCC-specific mortality were evaluated in the comparison of survival outcomes. Additionally, 5-year survival rates for each of these outcomes were determined. Pathologic outcomes, including tumor size, pathological T (pT) stage, histologic type, proportion of Fuhrman grade 3/4, presence of sarcomatoid differentiation, necrosis, lymphovascular invasion, capsular invasion, and margin positivity, were evaluated. As a subanalysis, hazard ratios (HRs) for factors influencing overall survival (OS) and recurrence-free survival (RFS) were examined.

2. Statistical Analysis

Propensity score matching (PSM) was performed using the “MatchIt” R package with a 1:3 matching ratio and the ‘optimal’ method. The variables used for matching were the eGFR and RENAL score risk group. The independent t-test and chi-square test were employed to compare the PN and RN arms. Kaplan-Meier (KM) curves were used to analyze OS, cancer-specific survival (CSS), and RFS. Cox regression univariable and multivariable analyses were conducted to identify risk factors associated with OS and RFS. The variables included in the Cox regression analysis were age, sex, BMI, history of DM, history of HTN, smoking history, CRP level, NLR level, PN operative method, pT stage, Furhman grade 3/4, sarcomatoid differentiation, necrosis, capsular invasion, and lymphovascular invasion. All statistical analyses were performed using IBM SPSS Statistics ver. 29.0 (IBM Co., Armonk, NY, USA) and R Statistics ver. 4.3.1 (R Foundation for Statistical Computing, Vienna, Austria). A p-value of less than 0.05 was considered to indicate statistical significance.

3. Operative Methods

The surgical procedures included open, laparoscopic, hand-assisted laparoscopic, and robot-assisted laparoscopic methods. The open approach encompassed both retroperitoneal and transperitoneal techniques. Conversely, the laparoscopic and hand-assisted laparoscopic procedures were exclusively performed using the transperitoneal route, with 3 to 4 ports. Similarly, robot-assisted laparoscopic procedures were conducted transperitoneally, utilizing 4 ports along with an additional 1 or 2 assistant ports. All PNs were performed under warm ischemia, employing either bulldog or Satinsky clamps.

RESULTS

A total of 740 patients were included in this study. Prior to PSM, the PN arm comprised 53 patients, while the RN arm included 687 patients. Baseline characteristics before PSM are presented in Supplementary Table 1. The PN arm demonstrated a significantly higher eGFR compared to the RN arm (92.0 mL/min/1.73 m2 vs. 77.0 mL/min/1.73 m2, p<0.001), along with a significantly lower RENAL nephrometry score (9.0 vs. 10.1, p<0.001). Additionally, the PN arm had a substantially higher percentage of clinical T2a (cT2a) cases (86.3% vs. 73.2%, p=0.041). After PSM, the PN arm consisted of 44 patients, while the RN arm included 132. Baseline characteristics following PSM are detailed in Table 1. Following PSM, no significant differences were noted between the PN and RN arms, with the exception of laterality (68.2% vs. 48.5%, p=0.023) (Table 1).

Baseline characteristics

1. Perioperative Outcomes

Table 2 delineates the perioperative outcomes for each arm. The operative time was longer for the PN arm (169.0 minutes vs. 150.4 minutes, p=0.042). No significant difference was found in the type of operation; however, the use of the robotic method was more prevalent in the PN arm (79.5% vs. 44.7%). The intraoperative complication rate was lower in the PN arm (2.3% vs. 12.9%, p=0.044), whereas the postoperative complication rate was higher in that arm (22.7% vs. 9.8%, p=0.028). Furthermore, complications of Clavien-Dindo classification grade III or higher were significantly more frequent in the PN arm (11.4% vs. 0.08%, p<0.001). Urological complications of Clavien-Dindo classification grade III or higher were also more prevalent among the arm receiving PN (6.8% vs. 0%, p=0.015). Complication rates for open and minimally invasive surgical procedures are available in Supplementary Table 2.

Perioperative and postoperative outcomes

At follow-up, the PN arm displayed significantly better renal function. The incidence of de novo CKD in the sixth postoperative month was 3.1% in the PN compared to 37.6% in the RN arm. This indicates that the incidence in the RN arm was over 12 times higher than that in the PN arm (p<0.001).

2. Pathology

Pathologic outcomes are presented in Table 3. A significant difference was noted in the distribution of pT stages between the 2 arms (p=0.006), with PN displaying a higher proportion of pT1 (45.5% vs. 21.2%). Other microscopic findings, including positive margins (0.0% vs. 0.8%, p>0.999), Fuhrman grade 3/4 (69.8% vs. 77.6%, p=0.302), sarcomatoid differentiation (7.0% vs. 11.3%, p=0.420), necrosis (25.0% vs. 39.3%, p=0.088), lymphovascular invasion (2.3% vs. 6.8%, p=0.259), and capsular invasion (30.2% vs. 37.5%, p=0.389), were not significantly different between the arms.

Pathologic outcomes

3. Oncologic Outcomes

The KM curves revealed no significant differences in OS, CSS, or RFS between the 2 arms (p=0.192, p=0.289, and p=0.471, respectively) (Fig. 1). In the 5-year survival analysis, the RN arm exhibited a 5-year OS rate of 94.4%, compared to a 100% rate in the PN arm. In comparison, the RN arm displayed a 5-year CSS rate of 96.3%, while the PN arm demonstrated a rate of 100%. Regarding RFS, the RN arm had a rate of 80.8%, and the PN arm had a rate of 93.1%.

Fig. 1.

(A) Overall survival Kaplan-Meier curve of radical nephrectomy and partial nephrectomy patients. (B) Cancer-specific survival Kaplan-Meier curve of radical nephrectomy and partial nephrectomy patients. (C) Recurrence-free survival Kaplan-Meier curve of radical nephrectomy and partial nephrectomy patients.

4. Subanalysis

Following Cox regression analysis for OS, no significant risk factors for OS were identified, perhaps due to an insufficient number of events for analysis. The results of the HR analysis for RFS in cT2 RCC are presented in Table 4. Univariable Cox regression analysis revealed significant associations for CRP levels (HR, 1.128; 95% confidence interval [CI], 1.047–1.216), necrosis (HR, 2.572; 95% CI, 1.150–9.688), capsular invasion (HR, 2.674; 95% CI, 1.172– 6.102), and lymphovascular invasion (HR, 5.047; 95% CI, 1.133–22.470). PN did not significantly impact RFS (HR, 0.675; 95% CI, 0.230–1.979). However, in the multivariable Cox regression analysis, CRP levels remained a significant factor (HR, 1.127; 95% CI, 1.045–1.215).

Recurrence-free survival Cox regression study

DISCUSSION

This study compared the outcomes of PN and RN for the treatment of cT2 RCC. Survival analysis using KM curves for OS, CSS, and RFS revealed no significant differences between arms. Subanalysis demonstrated that the use of PN did not significantly influence RFS; however, RFS was significantly associated with CRP levels. Urologic complications, including acute kidney injury and urine leakage, contributed to a greater incidence of Clavien-Dindo classification grade III or higher complications in the PN arm. Urine leakage was classified as a Clavien-Dindo classification grade III complication due to the need for additional intervention, specifically the placement of a ureteral stent. However, the PN arm included only 1 case of de novo CKD at 6 months postoperatively, in contrast to its occurrence in nearly onethird of the patients in the RN arm.

In a systematic review and meta-analysis, Huang et al. [14] revealed that compared to RN, PN—a more technically demanding surgery—necessitates a longer operative time and results in greater intraoperative blood loss. In our study, the operative time was significantly longer for PN than RN; however, EBL did not differ significantly between the arms. Despite the absence of a significant difference in EBL, the higher frequency of complications underscores the technically challenging nature of the procedure.

Several studies have examined survival outcomes for cT2 RCC. Bertolo et al. [15] reported an all-cause mortality rate of 3.3%, a cancer-specific mortality rate of 0.8%, and a recurrence rate of 10% after robot-assisted laparoscopic PN for cT2a RCC. Klett et al. [11] found no significant difference in OS, CSS, or metastasis-free survival between RN and PN. Similarly, a multicenter study by Kopp et al. [16] on cT2 RCC revealed no significant difference in OS, CSS, or progressionfree survival. An investigation of cT2 RCC conducted by Alanee et al. indicated that PN and RN yielded comparable results in terms of CSS [12]. Amparore et al. [17] compared the 5-year survival of cT2 RCC between PN and RN and found no significant difference in all-cause or cancer-specific mortality. However, some research suggests that PN may be associated with superior OS outcomes [18]. After reviewing several studies on cT2 RCC, we conclude that the oncologic outcomes of PN and RN are similar. In our study, KM curves also displayed no significant differences between PN and RN in OS, CSS, or RFS.

The results of this study suggest a lower complication rate than those reported in previous research [15,19-21]. PN carries an inherently higher risk of complications compared to RN because it involves breaching the collecting system, potentially leading to the development of pseudoaneurysms after renorrhaphy. De novo CKD has been shown to occur in approximately half of cases following RN, whereas the incidence after PN is more variable and generally lower [3,22]. In our study, de novo CKD occurred in approximately one-third of the patients after RN, while only 1 case arose following PN. CKD is associated with reduced survival in patients with cancer, as noted by Lee et al. [23].

According to O’Brian et al. [24], elevated CRP levels are indicative of poor prognosis in urological cancers. Hu et al. [25] reported that a higher CRP concentration was associated with comparatively poor OS and CSS in cases of RCC. Additionally, elevated CRP levels have been associated with worse CSS and progression-free survival in patients with localized RCC [25]. Wu et al. [26] found that both OS and CSS were significantly associated with pooled HR, suggesting a connection between increased CRP and reduced survival in RCC. In our study, we confirmed an association between CRP level and RFS.

This study is notable for its utilization of data from multiple tertiary hospitals in Korea. However, the multicenter nature of the data may have introduced variations in the techniques employed for PN. The accuracy of renal function tracking was also compromised by incomplete follow-up data. Additionally, several biases are inherent to the retrospective nature of the study and the reliance on surgical data from tertiary hospitals. The exclusion of pN1 and pM1 cases further restricted the comparison of surgical outcomes in advanced RCC and limited the survival analysis. Preoperatively determining nodal status is challenging, which is another inherent limitation of retrospective study designs. The methods used, such as open surgery, handassisted laparoscopic surgery, pure laparoscopic surgery, and robotic-assisted laparoscopic surgery, are varied and may not reflect current surgical trends. We also attempted a Cox regression analysis for OS, but it did not yield meaningful results, presumably due to an insufficient number of events; thus, it was difficult to analyze the HRs for OS. Finally, the PSM process resulted in the removal of many cases, which likely contributed to the challenges regarding Cox analysis. Nevertheless, the use of PSM to address confounding variables and balance the data is another strength of the present study.

CONCLUSIONS

In cT2 RCC, PN demonstrated a lower incidence of de novo CKD compared to RN, with no significant differences in survival outcomes. These findings suggest that PN could represent a viable alternative to RN for select patients with cT2 RCC, offering comparable survival outcomes while reducing the risk of de novo CKD. Additional research and prospective studies are required to validate these findings in advanced RCC.

Supplementary Materials

Supplementary Tables 1-2 can be found via https://doi.org/10.22465/juo.244800360018.

Supplementary Table 1.

Prepropensity score matching baseline characteristics

juo-244800360018-Supplementary-Table-1.pdf
Supplementary Table 2.

The complication rates for open and nonopen (minimally invasive) surgeries

juo-244800360018-Supplementary-Table-2.pdf

Notes

Grant/Fund Support

This study received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Research Ethics

We performed this retrospective, multi-institutional study after Institutional Review Board (IRB) approval of Seoul National University Bundang Hospital (IRB approval number: B-2310-856-105) and in accordance with the ethical standards of the 1964 Declaration of Helsinki and its later amendments.

Conflicts of Interest

The authors have nothing to disclose.

Author Contribution

Conceptualization: JKK; Data curation: SSB, SKH, SL, CWJ, SHK, SHH, JYL, YJK, JC, ECH, TGK, JKK; Formal analysis: SSB, SKH, SL, CWJ, SHK, SHH, JYL, YJK, JC, ECH, TGK, JKK; Funding acquisition: SSB, SKH, SL, CWJ, SHK, SHH, JYL, YJK, JC, ECH, TGK, JKK; Methodology: JKK; Project administration: JKK; Visualization: YC; Writing - original draft: YC; Writing - review & editing: JKK.

Acknowledgements

We extend our gratitude to the Korean Renal Cell Carcinoma (KORCC) group for their assistance with data analysis.

References

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021;71:209–49.
2. Ljungberg B, Albiges L, Abu-Ghanem Y, Bedke J, Capitanio U, Dabestani S, et al. European Association of Urology guidelines on renal cell carcinoma: the 2022 update. Eur Urol 2022;82:399–410.
3. Huang WC, Levey AS, Serio AM, Snyder M, Vickers AJ, Raj GV, et al. Chronic kidney disease after nephrectomy in patients with renal cortical tumours: a retrospective cohort study. Lancet Oncol 2006;7:735–40.
4. Scosyrev E, Messing EM, Sylvester R, Campbell S, Van Poppel H. Renal function after nephron-sparing surgery versus radical nephrectomy: results from EORTC randomized trial 30904. Eur Urol 2014;65:372–7.
5. Lee RA, Strauss D, Kutikov A. Role of minimally invasive partial nephrectomy in the management of renal mass. Transl Androl Urol 2020;9:3140–8.
6. Miller DC, Schonlau M, Litwin MS, Lai J, Saigal CS, ; Urologic Diseases in America P. Renal and cardiovascular morbidity after partial or radical nephrectomy. Cancer 2008;112:511–20.
7. Tan HJ, Norton EC, Ye Z, Hafez KS, Gore JL, Miller DC. Long-term survival following partial vs radical nephrectomy among older patients with early-stage kidney cancer. JAMA 2012;307:1629–35.
8. Thompson RH, Boorjian SA, Lohse CM, Leibovich BC, Kwon ED, Cheville JC, et al. Radical nephrectomy for pT1a renal masses may be associated with decreased overall survival compared with partial nephrectomy. J Urol 2008;179:468–71. discussion 472-3.
9. Thompson RH, Siddiqui S, Lohse CM, Leibovich BC, Russo P, Blute ML. Partial versus radical nephrectomy for 4 to 7 cm renal cortical tumors. J Urol 2009;182:2601–6.
10. Nahar B, Gonzalgo ML. What is the current role of partial nephrectomy for T2 tumors? Can J Urol 2017;24:8698–704.
11. Klett DE, Tsivian M, Packiam VT, Lohse CM, Ahmed ME, Potretzke TA, et al. Partial versus radical nephrectomy in clinical T2 renal masses. Int J Urol 2021;28:1149–54.
12. Alanee S, Herberts M, Holland B, Dynda D. Contemporary experience with partial nephrectomy for stage T2 or greater renal tumors. Curr Urol Rep 2016;17:5.
13. Byun SS, Hong SK, Lee S, Kook HR, Lee E, Kim HH, et al. The establishment of KORCC (KOrean Renal Cell Carcinoma) database. Investig Clin Urol 2016;57:50–7.
14. Huang R, Zhang C, Wang X, Hu H. Partial nephrectomy versus radical nephrectomy for clinical T2 or higher stage renal tumors: a systematic review and meta-analysis. Front Oncol 2021;11:680842.
15. Bertolo R, Autorino R, Simone G, Derweesh I, Garisto JD, Minervini A, et al. Outcomes of robot-assisted partial nephrectomy for clinical T2 renal tumors: a multicenter analysis (ROSULA Collaborative Group). Eur Urol 2018;74:226–32.
16. Kopp RP, Mehrazin R, Palazzi KL, Liss MA, Jabaji R, Mirheydar HS, et al. Survival outcomes after radical and partial nephrectomy for clinical T2 renal tumours categorised by R.E.N.A.L. nephrometry score. BJU Int 2014;114:708–18.
17. Amparore D, Pecoraro A, Piramide F, Checcucci E, DE Cillis S, Volpi G, et al. Comparison between minimally-invasive partial and radical nephrectomy for the treatment of clinical T2 renal masses: results of a 10-year study in a tertiary care center. Minerva Urol Nephrol 2021;73:509–17.
18. Shum CF, Bahler CD, Sundaram CP. Matched comparison between partial nephrectomy and radical nephrectomy for T2 N0 M0 tumors, a study based on the national cancer database. J Endourol 2017;31:800–5.
19. Muhlbauer J, Kowalewski KF, Walach MT, Porubsky S, Wessels F, Nuhn P, et al. Partial nephrectomy preserves renal function without increasing the risk of complications compared with radical nephrectomy for renal cell carcinomas of stages pT2-3a. Int J Urol 2020;27:906–13.
20. Bradshaw AW, Autorino R, Simone G, Yang B, Uzzo RG, Porpiglia F, et al. Robotic partial nephrectomy vs minimally invasive radical nephrectomy for clinical T2a renal mass: a propensity score-matched comparison from the ROSULA (Robotic Surgery for Large Renal Mass) Collaborative Group. BJU Int 2020;126:114–23.
21. Beksac AT, Okhawere KE, Elbakry AA, Dayal BD, Paulucci DJ, Rothberg MB, et al. Management of high complexity renal masses in partial nephrectomy: a multicenter analysis. Urol Oncol 2019;37:437–44.
22. Kopp RP, Liss MA, Mehrazin R, Wang S, Lee HJ, Jabaji R, et al. Analysis of renal functional outcomes after radical or partial nephrectomy for renal masses >/=7 cm using the RENAL score. Urology 2015;86:312–9.
23. Lee M, Wang Q, Wanchoo R, Eswarappa M, Deshpande P, Sise ME. Chronic kidney disease in cancer survivors. Adv Chronic Kidney Dis 2021;28:469–76. e1.
24. O’Brian D, Prunty M, Hill A, Shoag J. The role of C-reactive protein in kidney, bladder, and prostate cancers. Front Immunol 2021;12:721989.
25. Hu Q, Gou Y, Sun C, Ding W, Xu K, Gu B, et al. The prognostic value of C-reactive protein in renal cell carcinoma: a systematic review and meta-analysis. Urol Oncol 2014;32:50.e1–8.
26. Wu Y, Fu X, Zhu X, He X, Zou C, Han Y, et al. Prognostic role of systemic inflammatory response in renal cell carcinoma: a systematic review and meta-analysis. J Cancer Res Clin Oncol 2011;137:887–96.

Article information Continued

Fig. 1.

(A) Overall survival Kaplan-Meier curve of radical nephrectomy and partial nephrectomy patients. (B) Cancer-specific survival Kaplan-Meier curve of radical nephrectomy and partial nephrectomy patients. (C) Recurrence-free survival Kaplan-Meier curve of radical nephrectomy and partial nephrectomy patients.

Table 1.

Baseline characteristics

Variable PN RN p-value
Age (yr) 53.6±14.1 53.7±13.0 0.950
Male sex 33 (75.0) 78 (59.1) 0.058
Body mass index (kg/m2) 25.4±3.6 24.7±3.6 0.251
Diabetes mellitus 8 (18.2) 16 (12.1) 0.310
Hypertension 19 (43.2) 54 (40.9) 0.791
Smoking history 18 (40.9) 54 (41.5) 0.942
ASA PS classification grade≥III 1 (2.3) 5 (4.0) >0.999
Creatinine (mg/dL) 0.86±0.22 0.83±0.20 0.348
CRP (mg/dL) 0.75±2.83 1.85±3.74 0.061
NLR 2.3±1.1 3.5±8.0 0.300
EGFR (mL/min/1.73 m2) 93.1±24.3 91.7±20.0 0.715
Radiologic tumor size (mm) 81.2±21.6 84.9±17.0 0.243
RENAL score 9.0±1.9 9.6±1.5 0.051
RENAL score risk group >0.999
 Low risk 6 (13.6) 6 (4.5)
 Intermediate 18 (40.9) 53 (40.2)
 High 20 (45.5) 73 (55.3)
Symptom at diagnosis 10 (22.7) 47 (35.6) 0.114
Laterality, left 30 (68.2) 64 (48.5) 0.023
Clinical T stage 0.341
 2a 39 (88.6) 109 (82.6)
 2b 5 (11.4) 23 (17.4)

Values are presented as mean±standard deviation or number (%).

PN, partial nephrectomy arm; RN, radical nephrectomy arm; ASA PS, American Society of Anesthesiologists physical status; CRP, C-reactive protein; NLR, neutrophillymphocyte ratio; eGFR, estimated glomerular filtration rate; RENAL score, radius, exophytic/endophytic, nearness to collecting system or sinus, anterior/posterior, and location relative to polar lines score.

Fisher exact test.

Table 2.

Perioperative and postoperative outcomes

Variable PN RN p-value
Operation time (min) 169.0±51.4 150.4±51.8 0.042
Operation type <0.001
 Robotic 35 (79.5) 59 (44.7)
 Laparoscopic 1 (2.3) 44 (33.3)
 Open 8 (18.2) 29 (22.0)
Ischemic time (min) 29.1±9.5 - -
Estimated blood loss (mL) 218.2±164.1 232.4±255.6 0.375
Intraoperative complication 1 (2.3) 17 (12.9) 0.044
Postoperative complication 10 (22.7) 13 (9.8) 0.028
Postoperative complication, Clavien-Dindo classification grade≥III 5 (11.4) 0 (0) <0.001
Postoperative urologic complication 4 (9.1) 3 (2.3) 0.045
Postoperative urologic complication, Clavien-Dindo classification grade≥III 3 (6.8) 0 (0) 0.015
Postoperative month 1 creatinine (mg/dL) 0.96±0.22 1.24±0.88 0.031
Postoperative month 1 eGFR (mL/min/1.73 m2) 80.9±20.2 61.3±14.5 <0.001
Postoperative month 3 creatinine(mg/dL) 0.95±0.19 1.25±1.17 0.118
Postoperative month 3 eGFR (mL/min/1.73 m2) 81.4±16.7 62.6±16.6 <0.001
Postoperative month 6 creatinine (mg/dL) 0.89±0.20 1.29±1.55 0.090
Postoperative month 6 eGFR (mL/min/1.73 m2) 87.6±21.2 61.5±13.3 <0.001
6-Month de novo CKD 1 (3.1) 41 (37.6) <0.001
Follow-up (mo) 37.9±39.8 46.0±42.7 0.268

Values are presented as mean±standard deviation or number (%).

PN, partial nephrectomy arm; RN, radical nephrectomy arm; eGFR, estimated glomerular filtration rate; CKD, chronic kidney disease.

Fisher exact test.

Hand-assisted laparoscopic, single port laparoscopic, and 3–4 port laparoscopic included.

Table 3.

Pathologic outcomes

Variable PN RN p-value
Tumor size (mm) 76.8±24.0 83.6±20.8 0.074
Pathologic T stage 0.006
 1 20 (45.5) 28 (21.2)
 2 17 (38.6) 67 (50.8)
 3 6 (13.6) 18 (13.6)
 4 1 (2.3) 19 (14.4)
Histology, type 0.559
 Clear cell 31 (70.5) 103 (78.0)
 Papillary 1 (2.3) 3 (2.3)
 Chromophobe 6 (13.6) 17 (12.9)
 Other malignancy 6 (13.6) 9 (6.8)
Margin positive 0 (0) 1 (0.8) >0.999
Furhman grade 3/4 30 (69.8) 97 (77.6) 0.302
Sarcomatoid differentiation 3 (7.0) 14 (11.3) 0.420
Necrosis 11 (25.0) 48 (39.3) 0.088
Lymphovascular invasion 1 (2.3) 9 (6.8) 0.259
Capsular invasion 13 (30.2) 48 (37.5) 0.389
Recurrence 4 (9.1) 20 (15.2) 0.310
Death
 All cause 0 (0) 6 (4.5) 0.339
 Renal cell carcinoma specific 0 (0) 4 (3.1) 0.573

Values are presented as mean±standard deviation or number (%).

PN, partial nephrectomy arm; RN, radical nephrectomy arm.

Fisher exact test.

Table 4.

Recurrence-free survival Cox regression study

Variable Univariable
Multivariable
HR 95% CI p-value HR 95% CI p-value
Age (yr) 1.028 0.996–1.061 0.088 - - -
Male sex 1.099 0.479–2.518 0.824 - - -
Body mass index (kg/m2) 0.910 0.798–1.038 0.161 - - -
Diabetes mellitus 0.753 0.174–3.263 0.705 - - -
Hypertension 1.110 0.488–2.527 0.803 - - -
Smoking history 0.921 0.401–2.116 0.847 - - -
CRP (mg/dL) 1.128 1.047–1.216 0.002 1.127 1.045–1.215 0.002
NLR 0.976 0.886–1.076 0.629 - - -
Partial nephrectomy 0.675 0.230–1.979 0.474 - - -
Pathologic T stage
 1 - - - - - -
 2 0.502 0.193–1.304 0.157 - - -
 3 0.651 0.197–2.150 0.481 - - -
 4 0.876 0.234–3.276 0.844 - - -
Furhman grade 3/4 1.852 0.678–5.054 0.229 - - -
Sarcomatoid differentiation 0.984 0.230–4.213 0.983 - - -
Necrosis 2.572 1.150–5.751 0.021 - - -
Capsule invasion 2.674 1.172–6.102 0.019 - - -
Lymphovascular invasion 5.047 1.133–22.470 0.034 - - -

HR, hazard ratio; CI, confidence interval; CRP, C-reactive protein; NLR, neutrophil-lymphocyte ratio.